Walter E. Finkbeiner, MD, PhD

Professor Emeritus
Pathology
Specialty Areas
Autopsy
Fetal Pathology
Experimental Pathology
Hospital Affiliations
Zuckerberg San Francisco General Hospital
Research and Clinical Interests

My major clinical interests include autopsy pathology, fetal pathology, forensic medicine and pulmonary pathology. My basic research interest focuses on the pathology and pathophysiology of the chronic airway diseases, particularly cystic fibrosis (CF), chronic bronchitis and asthma. Using in vitro models of airway surface epithelial and gland cells along with human tissue samples, our laboratory studies differentiation of the airway epithelium, regulation of airway secretion, composition of respiratory mucus, and mechanisms underlying airway gland hyperplasia. We also develop airway cell models for high throughput screening and CF drug discovery.

Selected Publications
  • Sun DI, Tasca A, Haas M, Baltazar G,Harland RM, Finkbeiner WE, Walented P. Na+/H+ Exchangers are required for the development and function of vertebrate mucociliary epithelia. Cells Tissues Organs. 2018 (in press).
  • Phuan PW, Son JH, Tan JA, Li C, Musante I, Zlock L, Nielson DW, Finkbeiner WE, Kurth MJ, Galietta LJ, Haggie PM, Verkman AS. Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators. J Cyst Fibros 17:595-606, 2018.
  • Sun DI, Tasca A, Haas M, Baltazar G,Harland RM, Finkbeiner WE, Walented P. Na+/H+ Exchangers are required for the development and function of vertebrate mucociliary epithelia. Cells Tissues Organs. 2018 (in press).
  • Phuan PW, Veit G, Tan JA, Roldan A, Finkbeiner WE, Haggie PM, Lukacs GL, Verkman AS. ΔF508-CFTR Modulator Screen Based on Cell Surface Targeting of a Chimeric Nucleotide Binding Domain 1 Reporter. SLAS Discov.23(8):823-831. doi: 10.1177/2472555218763310. Epub 2018
  • Lachowicz-Scroggins ME, Finkbeiner WE, Gordon ED, Yuan S, Zlock L, Bhakta NR, Woodruff PG, Fahy JV, Boushey HA. Corticosteroid and long-acting ß-agonist therapy reduces epithelial goblet cell metaplasia. Clin Exp Allergy. 47:1534-1545, 2017.
Additional Information